甘精胰岛素联合格列美脲治疗在改善长期2型糖尿病患者血糖水平和药物耐受中的应用

摘要

目的 探讨甘精胰岛素联合格列美脲治疗在改善长期2型糖尿病患者血糖水平和药物耐受中的应用价值.方法 前瞻性选取2014年1月至2017年1月期间治疗的长期2型糖尿病患者136例,采用随机数字表法将其分为两组,各68例.观察组采用甘精胰岛素联合格列美脲治疗,对照组采用精蛋白生物合成人胰岛素联合格列美脲治疗.比较两组血糖水平、胰岛功能与药物耐受情况的差异.结果 治疗前,两组空腹血糖(FBG)、餐后2 h血糖(2 h PBG)、糖化血红蛋白(HbA1c)水平比较,差异无统计学意义(P>0.05);治疗后,全部患者上述指标均明显低于治疗前,其中观察组上述指标均明显低于对照组,比较差异具有统计学意义(P0.05),治疗后,全部患者Fins、2Pins、FCP、PCP、HOMA-β均明显高于治疗前,观察组上述指标均明显高于对照组(P 0. 05),after treatment,the above indicators of all patients were significantly lower than those of pre - therapy,the indexes of observation group were obviously lower than those of the control group with statistically significant differ-ences (P 0. 05),after treatment,Fins,2 Pins,FCP,PCP,HOMA - β of all patients were significantly higher than those of pre - therapy,the above indexes of observa-tion group were obviously higher than those of control group(P < 0. 05),HOMA - IR of all patients were significantly lower than those of pre -therapy (P < 0. 05). Hypoglycemic events of observation group was obviously higher than that of control group(P < 0. 05). Conclusion Insulin Glargine combined Glimepiride therapy helps to ideal control blood - glucose levels,improve islet function for patients with long - term type 2 dia-betes insulin,and drug resistance is better. It is worthy of clinical popularization and application.